Table 3.
The association between duration of filled prescriptions and the risk of EAC. Cases were patients with BE and EAC, and controls were patients with BE and no EAC at the time of diagnosis or corresponding case.
| Duration of filled prescriptions (months) | Cases n (%) | Controls n (%) | Incidence Density Ratio (95% CI) | Cochrane-Armitage trend test p-value |
|---|---|---|---|---|
| Number of patients | 116 | 696 | ||
| PPI | ||||
| 0 | 6 (5.2) | 43 (6.2) | Reference | |
| >0 to 12 | 62 (53.5) | 328 (47.1) | 1.39 (0.33–3.41) | |
| >12 to 24 | 31 (26.7) | 219 (31.5) | 0.89 (0.33–2.36) | |
| >24 | 17 (14.7) | 106 (15.2) | 1.00 (0.33–3.00) | |
| NSAIDs/aspirin* | 0.30 | |||
| 0 | 59 (50.9) | 285 (41.0) | Reference | |
| >0 to 12 | 43 (37.1) | 295 (42.4) | 0.70 (0.46–1.07) | |
| >12 | 14 (12.1) | 116 (16.6) | 0.55 (0.29–1.06) | |
| Statins* | 0.02 | |||
| 0 | 75 (64.7) | 360 (51.7) | Reference | |
| >0 to 12 | 23 (19.8) | 175 (25.1) | 0.63 (0.38–1.06) | |
| >12 | 18 (15.5) | 161 (23.2) | 0.52 (0.30–0.91) | |
*
>24 months was not examined because <5% of patients were in this category.